In this study we could demonstrate that a) IL-23 signalling may be involved in the early, rather than late, progression of colorectal cancer, b) nuclear expression of IL-23p19 is a marker of early disease and c) the beneficial prognostic impact of nuclear IL-23p19 may be restricted to patients with high anti-tumour T-cell responses. Here, IL23A is linked to colorectal cancer.